Skip to main content

Table 4 Floor and ceiling of generic and condition-specific measures at baseline and week 24a

From: Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis

 

EQ-5D-3L trials

SF-6D trial

% at floor

% at ceiling

% at floor

% at ceiling

Baseline

24 weeksb

Baseline

24 weeksb

Baseline

24 weeksb

Baseline

24 weeksb

N

997

951

997

951

441

441

416

416

CFQ-R-8D

        

CFQ-R-8D utility

0.00

0.00

1.70

3.68

0.00

0.00

1.81

3.85

Physical Functioning

0.70

1.89

72.42

69.09

1.36

2.16

63.04

64.18

Role Functioning

0.90

2.52

73.62

69.93

1.81

1.20

70.29

74.52

Emotion

1.00

0.63

39.92

50.37

0.91

1.20

40.36

45.67

Vitality

1.50

1.47

37.61

40.48

1.81

1.92

41.72

42.55

Breathing Difficulty

0.70

0.32

53.86

52.68

0.23

0.72

51.93

57.69

Cough

10.53

9.67

5.22

10.09

9.30

8.17

4.31

6.73

Abdominal Pain

0.60

0.74

59.58

58.99

0.68

1.20

53.74

53.37

Body Image

1.20

1.26

64.19

64.25

1.36

1.92

64.63

62.74

EQ-5D-3L

        

EQ-5D-3L utility

0.00

0.00

60.88

62.36

Mobility

0.00

0.00

95.39

93.06

Self-care

0.00

0.11

99.70

99.37

Usual activities

0.10

0.21

88.37

85.59

Pain/discomfort

0.40

0.74

73.62

75.81

Depression/anxiety

0.40

0.42

80.74

81.49

SF-6D

        

SF-6D utility

0.00

0.00

5.44

8.65

Physical functioning

8.16

7.71

55.56

61.20

Role limitation

23.81

22.84

48.53

52.64

Social functioning

0.68

0.24

63.04

64.90

Pain

0.45

0.72

74.15

73.08

Mental health

0.68

0.24

55.33

58.17

Energy

5.44

5.53

7.48

10.10

CFRSD

0.00

0.00

1.81

3.85

  1. CFQ-R-8D indicates Cystic Fibrosis Questionnaire–Revised–8 Dimensions; CFRSD: Cystic Fibrosis Respiratory Symptom Diary; SF-6D: Short Form 6 dimensions
  2. a Pooled treatment and placebo arms
  3. b 24 weeks indicates follow-up at 24 weeks